Ahcc09 Stratum

13/12/2024

The AHCC09 STRATUM Study held its 1st interim safety analysis with the Data Safety & Monitoring Board (DSMB) earlier this month. We are pleased to share that the DSMB reports no safety concerns regarding the treatment combination of Y90 and Atezolizumab+Bevacizumab/Placebo and recommends the continuation of the study. We appreciate our DSMB members, Prof David Machin and Prof Thomas Leung flying in from UK and Hong Kong respectively, and Prof Jens Ricke for dialing into the meeting.

15/11/2024

The AHCC09 Steering Committee met up on 5 Nov 2024 for our 5th quarterly committee meeting. With 10 out of 12 sites having completed site initiation visit (SIV), we anticipate a sharp increase in recruitment rates across the 4 study countries.

The AHCC09 study has also recently met its first safety analysis timepoint, and we are happy to share that the 1st Data Safety Monitoring Board (DSMB) Meeting will be held in early Dec.

We look forward to achieving more study milestones in the coming months and in 2025!

26/07/2024

A great discussion during the 2nd Investigators' Meeting for the AHCC09 STRATUM trial with the local and overseas investigators joining both in-person and virtually!

07/06/2024

We are happy to share that the Site Initiation Visit (SIV) for Taipei Veterans General Hospital was successfully conducted on 5 Jun 2024. This marks a momentous moment for the first of five sites in Taiwan to be initiated for the trial. Protocol chair, Prof Pierce Chow, joined the SIV (virtually) and it was an engaging session with the site investigators.

29/05/2024

The AHCC09 STRATUM held our 4th Steering Committee Meeting yesterday at the National Cancer Centre Singapore. It was an interactive session on the discussion of the ongoing progress of the trial and our position in the current trial landscape for intermediate to advanced HCC. We look forward to achieving key trial milestones in the upcoming months which include the 2nd Investigators' Meeting in July and having more sites activated in the next quarter.

29/04/2024

We are pleased to announce that the SIV for Beijing Tsinghua Changgung Hospital has been successfully conducted. It is a great delight that Prof Pierce Chow, Protocol Chair of Ahcc09 Stratum was visiting Beijing and could attend the SIV in-person. The SIV was preceded by a tour of the impressive HPB centre and labs of the hospital.

The SIV was followed by an official launch ceremony of the trial at the Beijing Liver Cancer Summit. We look forward to achieving more milestones as the trial initiates more sites in the coming months!

01/02/2024

The site initiation visit for AHCC09 STRATUM trial was successfully conducted for National University Hospital, Singapore (NUH) (site PI: A/Prof Chee Cheng Ean) yesterday afternoon. With this, the trial has 5 active recruiting sites and we look forward achieving more study milestones in the upcoming months.

31/10/2023

The AHCC09 STRATUM trial held our 3rd Steering Committee Meeting on 17 Oct 2023, led by protocol chair, Pierce Chow. It was an afternoon spent on a fruitful multi-disciplinary discussion on the study protocol. This meaningful discussion comes at a timely point as the study will soon be initiating some of the overseas participating sites in the last quarter of 2023.

24/10/2023

Our team is pleased to share with you the IMbrave050 article from Lancet (IF: 168.9) ahead of print, along with the press release by NCCS. Prof Pierce Chow is the senior author of this landmark randomized controlled trial which is the first in the world to demonstrate an effective adjuvant therapy for patients with HCC. This successful study reflects well on our network and the thought leadership of Singapore’s clinical and translational science.

For AHCC09 STRATUM, this Phase II clinical trial (also led by Prof. Chow) employs Y90 with or without the same regimen of atezolizumab plus bevacizumab in locally advanced HCC patients. The positive results from IMbrave050 not only support the clinical use of such adjuvant therapy, but also validate the importance of trials like AHCC09 STRATUM that aim to study treatment efficacy of combining adjuvant therapy with other established treatment modalities (e.g., loco-regional therapy like Y90). As AHCC09 STRATUM progresses, we look forward to unveiling whether the addition of atezolizumab plus bevacizumab to Y90 improves clinical outcomes compared to Y90 alone.

https://www.eurekalert.org/news-releases/1005549
https://doi.org/10.1016/S0140-6736(23)01796-8

Unlike other common cancers, hepatocellular carcinoma (HCC) currently has no adjuvant treatment to reduce recurrence for patients after curative-intent resection or ablation Results of IMbrave050, a Phase III clinical trial, show....

06/06/2023

The 2nd day of the AHCC09 STRATUM Investigators' Meeting was held on 1st June and we are glad that we are able to host the meeting at the newly opened National Cancer Centre Singapore (NCCS) building. The meeting was successfully concluded with a closing address by Prof Pierce Chow. We look forward to the start up of the sites in the coming months ahead.

06/06/2023

On 31st May, the AHCC09 STRATUM trial held our 1st Investigators' Meeting at Academia, SGH campus. We are glad to be able to fly in the investigators and coordinators from the 9 overseas sites which will be participating in the trial. It was an afternoon of meaningful discussion touching on topics from the scientific and clinical basis of the trial, to the logistical and operational running of the trial.